Effects of uncoupling protein 2 -866G/A polymorphism on platelet reactivity and prognosis in Chinese patients with type 2 diabetes and ischemic stroke

References

• World Health Organization. World health statistics 2008, Switzerland.
   Google Scholar
• Jax TW, Peters AJ, Plehn G, Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes –a two year follow-up of 243 patients. Cardiovasc Diabetol 2009;7(8):48. doi: 10.1186/1475-2840-8-48.
   Google Scholar
• Bassand JP, Hamm CW, Ardissino D, Guidelines for the diagnosis and treatment of non-ST-segment elevation acutecoronary syndromes. Eur Heart J 2007;28:1598–660.
   PubMedGoogle Scholar
• Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res 2007;120:311–21.
   Google Scholar
• Reny JL, Moerloose P, De, Dauzat M, Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008;6:444–50.
   PubMed Web of Science ®Google Scholar
• Geisler T, Langer H, Wydymus M, Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420–25.
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Bestehorn HP, Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742–50.
   Google Scholar
• Cuisset T, Frere C, Quilici J, High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542–9.
   Google Scholar
• Bliden KP, DiChiara J, Tantry US, Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49:657–66.
   Google Scholar
• Buonamici P, Marcucci R, Migliorini A, Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312–7.
   PubMed Web of Science ®Google Scholar
• Huczek Z, Filipiak KJ, Kochman J, Baseline platelet reactivity in acute myocardial infarction treated with primary angioplasty - influence on myocardial reperfusion, left ventricular performance, and clinical events. Am Heart J 2007;154: 62–70.
   PubMed Web of Science ®Google Scholar
• Malek LA, Spiewak M, Filipiak KJ, Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes. Kardiol Pol 2007;65:40–5.
   PubMed Web of Science ®Google Scholar
• McLeod CJ, Aziz A, Jr Hoyt RF, Uncoupling proteins 2 and 3 function in concert to augment tolerance to cardiac ischemia. J Biol Chem 2005;280:33470–76.
   Google Scholar
• Esterbauer H, Schneitler C, Oberkofler H, A common polymorphism in the promoter of UCP-2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 2001;28:178–83.
   PubMedGoogle Scholar
• Krempler F, Esterbauer H, Weitgasser R, A functional polymorphism in the promoter of UCP-2 enhances obesity risk but reduces type 2 diabetes risk in obese middle-aged humans. Diabetes 2002;51:3331–5.
   Google Scholar
• Sesti G, Cardellini M, Marini MA, A common polymorphism in the promoter of UCP-2 contributes to the variation in insulin secretion in glucose-tolerant subjects. Diabetes 2003;52:1280–3.
   Google Scholar
• Wang H, Chu WS, Lu T, Uncoupling protein-2 polymorphisms in type 2 diabetes, obesity, and insulin secretion. Am J Physiol Endocrinol Metab 2004;286:e1–7.
   Google Scholar
• Sesti G, Cardellini M, Marini MA, A common polymorphism in the promoter of UCP-2 contributes to the variation in insulin secretion in glucose-tolerant subjects. Diabetes 2003;52:1280–3.
   Google Scholar
• Reis AF, Dubois-Laforgue D, Bellanné-Chantelot C, A polymorphism in the promoter of UCP-2 gene modulates lipid levels in patients with type 2 diabetes. Mol Genet Metab 2004;82:339–44.
   Google Scholar
• Chai Y, Gu B, Qiu JR, The uncoupling protein 2 -866G > A polymorphism is associated with the risk of Ischemic Stroke in Chinese type 2 Diabetic Patients. CNS Neurosci Ther 2012;18:636–40.
   Google Scholar
• Silber S, Albertsson P, Avilés FF, Guidelines for percutaneous coronary interventions. Eur Heart J 2005;26:804–47.
   Google Scholar
• Crescente M, Di Castelnuovo A, Iacoviello L, Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008;99:14–26.
   Google Scholar
• Enerback S, Jacobsson A, Simpson EM, Mice lacking mitochondrial uncoupling protein are cold –sensitive but not obese. Nature 1997;387:90–4.
   Google Scholar
• Krauss S, Zhang CY, Lowell BB. A significant portion of mitochondrial proton leak in intact thymocytes depends on expression of UCP-2. Proc Natl Acad Sci USA 2002;99:118–22.
   PubMed Web of Science ®Google Scholar
• Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. Nat Rev Neurosci 2008;9:36–45.
   Google Scholar
• Richard D, Clavel S, Huang Q, Uncoupling protein 2 in the brain: distribution and function. Biochem Soc Trans 2001;29:812–7.
   Google Scholar
• Mattiasson G, Sullivan PG. The emerging functions of UCP-2 in health, disease, and therapeutics. Antioxid Redox Signal 2006;8:1–38.
   Google Scholar
• Zhang CY, Baffy G, Perret P, Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 2001;105:745–55.
   Google Scholar
• Mattiasson G, Shamloo M, Gido G, Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma. Nat Med 2003;9: 1062–8.
   Google Scholar
• Esterbauer H, Schneitler C, Oberkofler H, A common polymorphism in the promoter of UCP-2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 2001;28:178–83.
   Google Scholar
• Oberkofler H, Iglseder B, Klein K, Associations of the UCP-2 gene locus with asymptomatic carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2005;25:604–10.
   PubMedGoogle Scholar
• Krempler F, Esterbauer H, Weitgasser R, A functional polymorphism in the promoter of UCP-2 enhances obesity risk but reduces type 2 diabetes risk in obese middle-aged humans. Diabetes 2002;51:3331–5.
   PubMedGoogle Scholar
• Yamasaki H, Sasaki H, Ogawa K, Uncoupling protein 2 promoter polymorphism -866G/A affects peripheral nerve dysfunction in Japanese type 2 diabetic patients. Diabetes Care 2006;29:888–94.
   PubMedGoogle Scholar
• Dhamrait SS, Stephens JW, Cooper JA, Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2. Eur Heart J 2004;25: 468–75.
   PubMedGoogle Scholar
• Oberkofler H, Iglseder B, Klein K, Associations of the UCP-2 gene locus with asymptomatic carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2005;25:604–10.
   PubMedGoogle Scholar
• Lev EI, Kornowski R, Vaknin-Assa H, Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol 2008;15:435–9.
   Google Scholar